Open an account

LifeMD

LFMDP · NASDAQ

$21.30−$0.422 (−1.94%)TodayMarket closed ·
Prev close $21.72

About LFMDP

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The company is headquartered in New York City, New York and currently employs 347 full-time employees. The company went IPO on 2001-07-11. The firm offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The firm owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.

Employees
350
Headquarters
New York City, New York
Listed
Jul 11, 2001
Sector
Health Care
Industry
Health Care Technology
Website
lifemd.com

LFMDP key statistics

Market cap
102.67M
Price-earnings ratio
0.00
Dividend yield
3.03%
Average volume
1.76K
Volume
1.79K
Open price
$21.24
High today
$21.45
Low today
$21.26
52 Week high
$24.20
52 Week low
$18.50

LifeMD (LFMDP) at a glance

LifeMD (LFMDP) last traded at $21.30, with a market cap of 102.67M, a price-to-earnings ratio of 0.00 and a dividend yield of 3.03%.

Today the stock has traded between $21.26 and $21.45. The current price is 0.2% above the day's low and 0.7% below its high.

Volume so far is 1.79K shares, in line with the average of 1.76K shares a day.

Over the past year LifeMD has ranged from $18.50 to $24.20, and now sits 49% of the way up that range.

LifeMD met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.16 per share against an estimate of -$0.1486.

LFMDP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 64.0% on average.

  1. Q3 FY24: reported -$0.14 per share against an estimate of -$0.121
  2. Q4 FY24: reported -$0.02 per share against an estimate of -$0.0525
  3. Q1 FY25: reported $0.01 per share against an estimate of -$0.0539
  4. Q2 FY25: reported -$0.06 per share against an estimate of -$0.0082
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0476
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.034
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.2264
  8. Q2 FY26: reported -$0.16 per share against an estimate of -$0.1486

LFMDP news

  • Press releaseGlobe Newswire

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

  • Press releaseGlobe Newswire

    UPDATE - LifeMD Reports Second Quarter 2026 Results

  • Press releaseGlobe Newswire

    LifeMD Reports Second Quarter 2026 Results

  • Press releaseGlobe Newswire

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

  • Press releaseGlobe Newswire

    LifeMD Appoints Umesh Sripad as Chief Technology Officer

  • Press releaseGlobe Newswire

    LifeMD Reports First Quarter 2026 Results

  • Press releaseGlobe Newswire

    LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

  • Press releaseGlobe Newswire

    LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Similar companies

Companies in the same industry as LifeMD

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.